Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Eisai Plans R&D Structure Revamp, Hoping To Turn The Development Tide

This article was originally published in PharmAsia News

Executive Summary

TOKYO - Eisai CEO Haruo Naito unveiled plans to revamp the company's research and development structure in hopes of having his employees produce better results, Naito told analysts Feb. 27 in Tokyo

You may also be interested in...



With Aricept Losses Looming, Eisai Looks To Emerging Markets, Flexibility For New Growth

Eisai has grappled with the looming patent expiration of its blockbuster Alzheimer's disease drug Aricept, and the company has found a combination of efficiency models and belt-tightening - along with a pretty aggressive push to establish an oncology franchise - to realize growth after 2011

With Aricept Losses Looming, Eisai Looks To Emerging Markets, Flexibility For New Growth

Eisai has grappled with the looming patent expiration of its blockbuster Alzheimer's disease drug Aricept, and the company has found a combination of efficiency models and belt-tightening - along with a pretty aggressive push to establish an oncology franchise - to realize growth after 2011

Zenyaku Kogyo Teams With Theraclone For Influenza Antibodies

Tokyo-based Zenyaku Kogyo is hoping Theraclone's I-STAR technology can kick-start the company's influenza vaccine development

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

SC071235

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel